Roche's Divarasib Shows Lung Cancer Survival Gains at ESMO

· Health · Switzerland · United States

Roche presented data at the ESMO Congress showing its next-generation KRAS-targeted therapy divarasib extended survival and improved disease control in patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer. Researchers from The University of Texas MD Anderson Cancer Center reported that patients lived significantly longer with the drug. STAT called it one of the more impressive data sets at this year's meeting. Divarasib belongs to the KRAS G12C inhibitor class, a field where rivals are already marketed; the new results could support Roche's case for a next-generation entrant in that lung cancer niche.

Why it matters：KRAS G12C is one of oncology's most contested targets, and a survival win for a next-generation agent would intensify competition and shape treatment sequencing in lung cancer.

Key points

  • The drug was tested in previously treated advanced KRAS G12C-mutant NSCLC.
  • MD Anderson researchers reported significantly longer survival and better disease control.
  • STAT described the data as among the more impressive at ESMO.

Sources (original reporting)

More stories from this day